{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:27:01Z","timestamp":1773120421014,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011684","name":"Crohn's and Colitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.cgh.2020.08.021","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T02:39:19Z","timestamp":1597199959000},"page":"2082-2092.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn\u2019s Disease"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6021-0419","authenticated-orcid":false,"given":"Frank I.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amneet K.","family":"Hans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Gerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blair","family":"Fennimore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravy K.","family":"Vajravelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.08.021_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.08.021_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.021_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.021_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib7","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.021_bib8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2020.08.021_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.08.021_bib12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00004836-200208000-00007","article-title":"Infliximab decreases resource use among patients with Crohn's disease","volume":"35","author":"Rubenstein","year":"2002","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2020.08.021_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.08.021_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2020.08.021_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.08.021_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.08.021_bib18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/0272989X08315241","article-title":"The half-cycle correction explained: two alternative pedagogical approaches","volume":"28","author":"Naimark","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cgh.2020.08.021_bib19","first-page":"1","article-title":"National vital statistics reports","volume":"59","author":"Arias","year":"2011","journal-title":"United States Life Tables, 2007"},{"key":"10.1016\/j.cgh.2020.08.021_bib20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1572-0241.2008.01836.x","article-title":"Immunosuppressant medications and mortality in inflammatory bowel disease","volume":"103","author":"Lewis","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.08.021_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.08.021_bib22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn\u2019s disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.021_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2011.09.017","article-title":"Adverse events do not outweigh benefits of combination therapy for Crohn\u2019s disease in a decision analytic model","volume":"10","author":"Siegel","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.08.021_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib25","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S1873-9946(14)60099-4","article-title":"Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn\u2019s disease: a meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.08.021_bib26","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib28","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.08.021_bib29","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/S0016-5085(11)63209-5","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies: Treat\u2122 Registry data with a mean of 5 years of follow-up","volume":"140","author":"Lichtenstein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.021_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","article-title":"The benefit to risk balance of combining infliximab with azathioprine varies with age: a Markov model","volume":"13","author":"Scott","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.08.021_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/ibd\/izx045","article-title":"Assessing the optimal position for vedolizumab in the treatment of ulcerative colitis: a simulation model","volume":"24","author":"Scott","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.08.021_bib32","author":"Howlader"},{"key":"10.1016\/j.cgh.2020.08.021_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.21655","article-title":"Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis","volume":"85","author":"Olin","year":"2010","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2020.08.021_bib34","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: the basics","volume":"12","author":"Weinstein","year":"2009","journal-title":"Value in Health"},{"key":"10.1016\/j.cgh.2020.08.021_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","article-title":"An evaluation of utility measurement in Crohn\u2019s disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.08.021_bib36","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.021_bib37","series-title":"Decision modelling for health economic evaluation","first-page":"77","article-title":"Chapter 4: making decision models probabilisitc","author":"Briggs","year":"2006"},{"key":"10.1016\/j.cgh.2020.08.021_bib38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.08.021_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.08.021_bib40","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/MIB.0b013e31828132cb","article-title":"Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review","volume":"19","author":"Lopez","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.08.021_bib41","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/ibd\/izy102","article-title":"Nonadherence to biologic therapies in inflammatory bowel disease","volume":"24","author":"Wentworth","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.08.021_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cgh.2019.05.010","article-title":"Variation among patients with Crohn\u2019s disease in benefit vs risk preferences and remission time equivalents","volume":"18","author":"Bewtra","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.08.021_bib43","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jval.2019.03.011","article-title":"Comparing the noncomparable: the need for equivalence measures that make sense in health-economic evaluations","volume":"22","author":"Johnson","year":"2019","journal-title":"Value in Health"},{"key":"10.1016\/j.cgh.2020.08.021_bib44","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","article-title":"The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model","volume":"13","author":"Scott","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.08.021_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.021_bib53","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib54","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.021_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520311307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520311307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:36:06Z","timestamp":1761543366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520311307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1542356520311307"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.08.021","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}